|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Expenses | |||||
| Research and development | |||||
| General and administrative | |||||
| Total expenses | |||||
| Loss from operations | |||||
| Foreign exchange losses | |||||
| Investment income | |||||
| Non-cash interest expense for the sale of future royalties | |||||
| Other income | |||||
| Loss on issuance of convertible preferred stock and warrants | |||||
| Warrant issuance cost | |||||
| Changes in fair value of the warrant liability | |||||
| Net (loss) income | |||||
| Net (loss) income per share, basic | |||||
| Weighted average shares outstanding, basic | |||||
| Net (loss) income per share, diluted | |||||
| Weighted average shares outstanding, diluted | |||||
Loading...
